Analgesic Efficacy of Adding Dexmedetomidine to Erector Spinae Plane Block Versus Subcostal Transverse Abdominis Plane Block in Laparoscopic Cholecystectomy
NCT ID: NCT07075913
Last Updated: 2025-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2024-05-01
2025-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexamethasone/ Erector Spinae Plane Block Analgesia in Laparoscopic Cholecystectomy
NCT05105997
Dexmedetomidine Infusion as an Analgesic Adjuvant During Laparoscopic Cholecystectomy
NCT03211871
Analgesia After Laparoscopic Cholecystectomy
NCT04715165
Unilateral Right-Sided Erector Spinae Plane Block for Analgesia in Laparoscopic Cholecystectomy: Does the Volume Matter? A Randomized Controlled Trial
NCT07027540
Subcostal Transversus Abdominis Block Versus Erector Spinae Block in Open Cholecystectomy
NCT06410911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The subcostal transverse abdominis plane (SCTAP) block is the deposition of local anesthetic in the transverse abdominis plane inferior and parallel to the costal margin.
Ultrasound-guided erector spinae plane block (ESPB) is a popular, interfascial regional technique initially described for managing thoracic neuropathic pain.
Dexmedetomidine is an alpha-2 adrenergic receptor agonist that has been the focus of interest due to its sedative, analgesic, perioperative sympatholytic, and cardiovascular-stabilizing effects, resulting in reduced anesthetic requirements.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I
Patients received an ultrasound-guided subcostal transverse abdominis plane block with injection of 10 ml bupivacaine 0.25 %, 5ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
Subcostal transverse abdominis plane block
Patients received an ultrasound-guided subcostal transverse abdominis plane block with injection of 10 ml bupivacaine 0.25 %, 5ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
Group II
Patients will receive an ultrasound-guided erector spinae plane block (ESPB) with injection of 10 ml bupivacaine 0.25%, 5 ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
Erector spinae plane block
Patients will receive an ultrasound-guided erector spinae plane block (ESPB) with injection of 10 ml bupivacaine 0.25%, 5 ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Subcostal transverse abdominis plane block
Patients received an ultrasound-guided subcostal transverse abdominis plane block with injection of 10 ml bupivacaine 0.25 %, 5ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
Erector spinae plane block
Patients will receive an ultrasound-guided erector spinae plane block (ESPB) with injection of 10 ml bupivacaine 0.25%, 5 ml lignocaine 2 % plus 0.5 μg/kg dexmedetomidine in a 20 ml volume.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* American Society of Anesthesiologists (ASA) physical status I and II.
* Patients were planned to undergo laparoscopic cholecystectomy.
Exclusion Criteria
* ASA III, IV.
* History of clinically significant cardiac, hepatic, renal, respiratory or neurological disease.
* Coagulopathy and bleeding disorders.
* Known allergy to any drug included in the study.
* Systemic or local infection at the puncture site.
* Body mass index (BMI) \>35 (kg/m2).
* Failed technique.
20 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kafrelsheikh University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lamees Elsayed Ali Soliman Shaloof
Resident of Anesthesia, Surgical Intensive Care and Pain Therapy, Faculty of Medicine, Kafr-Elsheikh University, Kafr-Elsheikh, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KFSIRB200-624
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.